![[Updated] Macro headwinds drive investors to 'globalised' healthcare assets](https://media.dealstreetasia.com/uploads/2017/05/heartbeat-healthcare-pixabay.jpg?fit=980,545&resize=1920,undefined&q=75)
Editor’s note: The article was updated on September 26 to correct the transaction size of LYFE Capital’s investment in Taiwan’s Bora Pharmaceuticals. Bora raised a total of $200 million in September 2024 by issuing its first overseas convertible bonds to investors including LYFE Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
